Picture EBD Group Biotech Showcase 2023 San Francisco 650x100px
Financing › Details

Clinical Microbiomics–BPCE: investment, 202210 investment €10m from Health for Life Capital II fund managed by Seventure Partners


Period Period 2022-10-11
Organisations Money taker Clinical Microbiomics A/S
  Group Clinical Microbiomics (Group)
  Money source Health for Life Capital II fund (HFL II)
  Group BPCE (Group)
Products Product microbiomics
  Product 2 venture capital
Person Person de Crémoux, Isabelle (BPCE 201110– CEO of Seventure Partners)

Seventure Partners. (10/11/22). "Press Release: Clinical Microbiomics Set to Accelerate Its Expansion with EUR 10 Million Investment from Health for Life Capital II Managed by Seventure Partners". Paris & Copenhagen.

> Clinical Microbiomics is a trusted partner to leading innovators in microbiome research across pharma/biotech, consumer health, and academic institutions

> Funds to be invested to further advance Clinical Microbiomics’ leading microbiome profiling and systems biology platform, and to expand into new offerings and markets

> This round was completed in exclusive process with Seventure Partners and its health and nutrition microbiome focused Health for Life Capital™ II fund

Paris and Copenhagen, October 11, 2022 – Seventure Partners, a worldwide leading microbiome venture capital, and Clinical Microbiomics A/S, a pioneering microbiome research company, today announced the completion of a financing in the Danish growth company.

The transaction confirms Seventure Partners position as leading investor in the fast-developing microbiome field, where they have backed growth companies with funding through “Health for Life™ I" and “Health for Life™ II” since 2013.

Microbiome science is widely proposed as the next frontier in addressing our most urgent health challenges. Organisations worldwide are exploring the potential for microbiome science to help people live better lives; from novel nutritional products and next-generation probiotics to new ways to diagnose, treat and prevent disease. However, the complexity of microbiome science remains a challenge in bringing new solutions to market.

Since its foundation in 2015, Clinical Microbiomics has been innovating at the forefront of microbiome science. The company is working with the world’s leading food and consumer health companies and is supporting the pharmaceutical industry in phase 3 clinical trials through its GCP-compliant microbiome research services. Importantly Clinical Microbiomics hosts the richest data-warehouse on the market with 30k+ samples linking 3M+ bacterial strains to clinical phenotypes. Clinical Microbiomics is a premium quality microbiome analysis company, particularly known for its pioneering work on clonal-level microbiome profiling that is recognized as the most sensitive, precise, and comprehensive in the field.

Together with researchers from the world’s most prominent academic institutions and innovative companies, microbiome scientists at Clinical Microbiomics are constantly pushing the boundaries of science to find the answers needed to impact health and disease.

Isabelle de Cremoux, CEO and managing partner at Seventure Partners, commented: “Incredible progress has been made in understanding the link between the microbiota and our health in the past years, but there is still much more to be accomplished. There is a lot of data available, but we need better tools to get more insights and standards for how to put it to practice. Clinical Microbiomics has a track-record of developing tools that can untangle the complexity of the microbiome and help researchers worldwide understand the mechanisms that impact health and disease. Our investment will enable Clinical Microbiomics to invest even further to lead the way with innovative concepts and services at pharma standards for this field, and we believe their work will play a critical role in unleashing the potential of microbiome science”.

The funds raised will be invested to further advance Clinical Microbiomics’ leading microbiome profiling and systems biology platform, and to expand the service offering within multi-omics data integration, as well as to build further presence in key markets starting with the US.

Anders Grøn, CEO at Clinical Microbiomics, commented: “Our vision is a world where people are healthier because we understand how to improve our inner ecology – the microbiome. We challenge the idea that the complexity of the microbiome prevents us from exploring its potential to tackle the
most pressing health questions of our time. Seventure Partners brings valuable experience across the microbiome field that will help us identify and address challenges across the sector, and their investment will enable us to expand our innovation programs, quality management systems, and strategic collaborations at a high pace to help researchers worldwide to bring new products and treatments to market.”

Clinical Microbiomics’ is located in Medicon Valley, one of the largest centres for microbiome research in the World, but the Company’s microbiome analysis services are offered worldwide to clients across sectors such as pharma, biotech, nutrition, food, feed, personal care, and consumer testing.



Mathilde Pinon
Global Marketing Manager, Clinical Microbiomics

Anders Grøn
CEO, Clinical Microbiomics

Isabelle de Cremoux
CEO and managing Partner, Seventure Partners

Notes to editors:

This is the first of three notifications related to Clinical Microbiomics that are expected to release during October 2022.

About Clinical Microbiomics

Our inner ecology – that delicate microbial ecosystem known as the microbiome – is the new frontier in human health. At Clinical Microbiomics, we exist to untangle its complexity in search of mechanisms that impact health and disease.

Identifying and understanding those mechanisms is like looking for a needle in a haystack and demands a truly interdisciplinary approach to microbiome science. Innovating at the forefront of the field, our team of leading scientists creates breakthrough bioinformatics tools and analytical concepts that set new standards for understanding and influencing the microbiome.

Clinical Microbiomics is proud to partner with researchers from the world’s most prominent academic institutions and leading biotech, consumer health and pharma companies. Operating as an extension of their research organizations, we work broader, analyse deeper, and connect the dots to help find the answers needed to impact health and disease.

For more details:

About Seventure Partners

Seventure Partners is a long-term equity investor who actively supports innovative companies aiming at generating positive impacts on Humankind, Society, Sustainability and the Planet.

With €900m net commitments under management as of the end of 2021, Seventure is a leading venture capital firm in Europe investing since 1997 in innovative businesses with high growth potential in 2 main fields: Life sciences (Health & digital Health, Nutrition, Foodtech, Blue Economy, Aquaculture, Animal & Agriculture, Sport & Wellness with a specific interest for MICROBIOME-related innovations ...) across Europe, Israel, Asia and North America and Digital technologies in Europe. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage, growth, pre-IPO and IPO.

With Health for Life Capital™ funds (160ME and 250ME) and its co-investments funds, Seventure is worldwide leader in microbiome investments with more than 20 microbiome companies in portfolio to date.

For more details:
Twitter: @seventurep

Record changed: 2022-10-28


Picture Campus Berlin-Buch GmbH GMP Basic Course Online 650x200px

More documents for Clinical Microbiomics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top